Drug Comparison
Liraglutide vs Survodutide: Complete Comparison
Choosing between Liraglutide and Survodutide depends on your specific metabolic goals, insurance coverage, and tolerability profile. Both are weight management options, but their mechanisms, efficacy data, and cost profiles differ in clinically meaningful ways.
⚠️ Medical Disclaimer
This page is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Discuss all treatment decisions with a licensed healthcare provider who knows your complete medical history. Individual results vary significantly from clinical trial averages.
Weight Loss
Survodutide
19.0% vs 8.0%
Lower Cash Cost
Liraglutide
$1,349/mo vs $9,999/mo
Dosing
Liraglutide
Daily vs Weekly
FDA Status
Approved 2014
Phase 3
Side-by-Side Comparison Table
| Feature | Liraglutide | Survodutide |
|---|---|---|
| Brand Name(s) | Victoza, Saxenda | |
| Mechanism | GLP-1 receptor agonist | GLP-1/Glucagon dual receptor agonist |
| FDA Status | Approved 2014 | Phase 3 |
| Mean Weight Loss | 8.0% (SCALE) | 19.0% (SYNCHRONIZE-1) |
| Starting Dose | 0.6 mg | 0.6 mg |
| Max Dose | 3.0 mg | 4.8 mg |
| Frequency | Daily | Weekly |
| Half-Life | 13 hrs | 168 hrs |
| Cash Price/Month | $1349 | N/A (investigational) |
| Prior Auth Required | Yes | No |
| Key Pivotal Trial | SCALE | SYNCHRONIZE-1 |
Weight Loss Efficacy: Liraglutide vs Survodutide
In their respective pivotal trials, Liraglutide achieved a mean weight loss of 8.0% (SCALE) while Survodutide achieved 19.0% (SYNCHRONIZE-1). This 11.0 percentage point difference represents a clinically meaningful gap, though direct head-to-head trial data between these specific agents may be limited.
Important caveat: These trials enrolled different populations (different BMI criteria, T2D vs non-diabetic, different geographies) and used different primary endpoints. Direct comparisons should be interpreted with caution.
Mechanism: How They Work Differently
Liraglutide is a GLP-1 receptor agonist. Survodutide is a GLP-1/Glucagon dual receptor agonist. Both medications work through the GLP-1 pathway but differ in their additional receptor targets, half-lives, and molecular structures.
Side Effects
Both Liraglutide and Survodutide share a similar GI side effect profile. Common side effects for both include: constipation, diarrhea, fatigue, injection-site reaction. These are typically most pronounced during dose escalation and improve with time.
Liraglutide-specific: headache. Survodutide-specific: decreased appetite
Cost Comparison
Cash pay prices vary significantly: Liraglutide lists at approximately $1349/month vs Survodutide at N/A (not commercially available). Both require prior authorization through most commercial insurers.
Which Is Right for You? Decision Guide
Consider Liraglutide if:
- ✓ Your insurance specifically covers Victoza
- ✓ Your prescriber has experience with Liraglutide
- ✓ You prefer daily injections for dose flexibility
- ✓ You have prior experience with GLP-1 receptor agonist agonists
Consider Survodutide if:
- ✓ Your insurance specifically covers Survodutide
- ✓ Higher weight loss efficacy is your primary goal
- ✓ Once-weekly injection is preferred
- ✓ Simpler GLP-1 only mechanism is preferred
Bottom line: The choice between Liraglutide and Survodutide is best made with your prescribing clinician, accounting for your specific medical history, insurance coverage, prior treatment response, and metabolic goals. Neither medication is universally superior for all patients.